Search the Newsreel

Neurocrine Biosciences, Inc. (NBIX) Stock Price, News, Quote & History

This Yahoo Finance page provides detailed stock information for Neurocrine Biosciences, Inc. (NBIX), including its current price, historical data, financial performance, analyst ratings, and company overview. It highlights key products like INGREZZA and several pipeline candidates for neurological and psychiatric disorders. The company's market …

Form 8K E. W. Scripps Co Class A For: 7 August By Investing.com

This article announces the filing of a Form 8K by E.W. Scripps Co Class A for August 7. It is a brief news item from Investing.com, providing basic information about the SEC filing. The content focuses solely on this financial disclosure, with no further …

Earnings call transcript: E.W. Scripps posts Q2 2026 loss, shares jump 24%

E.W. Scripps reported a significant Q2 2026 loss of $12.68 per share, largely due to a $1.1 billion non-cash impairment charge related to its Scripps Networks business, and revenue fell short of forecasts. Despite the headline loss, the company's shares jumped 24% in after-hours …

Analysts Are Updating Their Strata Critical Medical, Inc. (NASDAQ:SRTA) Estimates After Its Second-Quarter Results

Strata Critical Medical, Inc. (NASDAQ:SRTA) saw its shares rise 9.8% after its second-quarter results, despite a significant increase in statutory losses per share. Analysts have since updated their estimates, now predicting profitability for the company next year and a notable 12% improvement in 2026 …

Criteo (CRTO) CFO has 6,285 shares sold to cover tax withholding

Criteo S.A.'s Chief Financial Officer, Sarah JS Glickman, had 6,285 Ordinary Shares automatically sold on August 6, 2026, at $17.23 per share. This sale was conducted to cover tax withholding obligations stemming from the settlement of a previously reported equity award. After this transaction, …

Criteo S.A. (CRTO) CEO auto-sells 15,559 shares for tax withholding

Criteo S.A. (CRTO) CEO Michael Komasinski automatically sold 15,559 ordinary shares on August 6, 2026, at $17.23 per share. This sale was conducted to cover tax withholding obligations associated with the settlement of a previously reported equity award. Following this transaction, Komasinski directly holds …

Criteo S.A. (CRTO) legal chief sells shares to cover tax obligations

Criteo S.A.'s Chief Legal Officer, Damon Ryan, sold 6,178 Ordinary Shares on August 6, 2026, at $17.23 per share to cover tax withholding obligations from a prior equity award settlement. Following this transaction, Ryan directly holds 167,765 shares. The sale was automatic and not …

The E.W. Scripps Company (NASDAQ: SSP) hit by impairment, swings to $12.68 loss

Could 1 Tiny Biotech Topple Vertex Pharmaceuticals' Cystic Fibrosis Empire?

Vertex Pharmaceuticals (NASDAQ: VRTX) has dominated the market for cystic fibrosis (CF) medicines since it earned approval for its first drug in this niche in 2012. To this day, most of the company's revenue comes from its CF franchise. In the second quarter, Vertex …

Neurocrine Biosciences Begins Phase 1 Study of GLP-1/GIP/Glucagon Triple Agonist NBIP-'1968 for Obesity

Neurocrine Biosciences has initiated a Phase 1 clinical study for NBIP-'1968, a GLP-1/GIP/glucagon receptor triple agonist, as a treatment for obesity. This move signifies the company's entry into the multi-agonist incretin therapeutics market, aiming to address limitations of current GLP-1-based treatments such as gastrointestinal …

Carter's Q1 Earnings on The Horizon: What Should Investors Know?

Carter's (CRI) is set to report its first-quarter 2026 earnings, with analysts expecting top-line growth but a decline in the bottom line. Despite facing a challenging retail landscape and rising SG&A expenses, the company is projected to benefit from strong brand recognition, strategic investments …

Are Business Services Stocks Lagging Cricut (CRCT) This Year?

For those looking to find strong Business Services stocks, it is prudent to search for companies in the group that are outperforming their peers. Cricut, Inc. (CRCT) is a stock that can certainly grab the attention of many investors, but do its recent returns …

Critical Metals Corp (CRML) Stock News Today

E.W. Scripps Q2 Earnings Call Highlights

Key Points Interested in E.W. Scripps Company (The)? Here are five stocks we like better. Scripps reported a $12.68-per-share Q2 loss, heavily affected by a $1.1 billion non-cash impairment charge, restructuring costs and other one-time items. CEO Adam Symson said performance fell short of …

Scripps Reports Q2 2026 Earnings as Impairment Charge Drives Reported Loss

TV broadcasting studio ©RuslonV A $1.1 billion non-cash impairment charge weighed heavily on The E.W. Scripps Company's (NASDAQ:SSP) second-quarter 2026 results, although the media company continued to advance its transformation strategy, expand cost savings and reaffirm expectations for a strong political advertising year. Key …

Doubleview Gold Stock Surges 8.76% as Hat Project Exploration and Critical Metals Potential Attract Investor Interest

Goldman Sachs Keeps Their Hold Rating on Crispr Therapeutics AG (CRSP)

Goldman Sachs has reiterated a Hold rating for Crispr Therapeutics AG (CRSP) with a price target of $55.00. This follows similar Hold ratings from other analysts like Wells Fargo, though H.C. Wainwright maintained a Buy rating. The company recently reported quarterly revenue of $10.18 …

Cricut (NASDAQ:CRCT) Stock Rating Upgraded by Zacks Research

Criteo SA (CRTO) Q3 2025 Earnings Report - Results, Call & Slides

Criteo SA (CRTO) has released its Q2 2023 earnings report, exceeding analyst expectations. The company reported actual EPS of CHF0.40 against a consensus of CHF0.35, and actual revenue of CHF379.88M, significantly beating the expected CHF187.24M. However, year-over-year revenue growth showed a decline of 5.28%.

Dimensional Fund Advisors LP Sells 412,889 Shares of CRISPR Therapeutics AG $CRSP

Dimensional Fund Advisors LP significantly reduced its stake in CRISPR Therapeutics AG by 45.5% in the first quarter, selling 412,889 shares. Following the sale, the firm now owns 494,218 shares valued at $23.49 million. The article also covers recent analyst ratings, insider trading activity, …

Brazilian Critical Minerals Expands Capital Base Through Performance Rights Conversion

Criteo S.A. (CRTO) stock price, news, quote and history

This article provides a comprehensive overview of Criteo S.A. (CRTO), including its current stock price, market data, key financial metrics, and company profile. It details the company's business segments, recent performance against benchmarks, and analyst insights, offering a full picture for potential investors.

Crizac Ltd Q1FY27 standalone profit surges 27%, guides for flat FY27

Sei Investments Co. Purchases 78,834 Shares of Criteo S.A. $CRTO

Sei Investments Co. significantly increased its stake in Criteo S.A. by 47.2% during the first quarter, purchasing 78,834 additional shares, bringing its total to 246,026 shares valued at approximately $4.4 million. This move is part of broader institutional investor activity in CRTO, where institutional …

Australian Critical Minerals Ltd (ASX: ACM) Share Price, ACM Stock News, ACM Share Price & Updates

E.W. Scripps (SSP) Reports Q2 Loss, Misses Revenue Estimates

Carter's, Inc. (CRI) stock price, news, quote and history

This article provides a comprehensive overview of Carter's, Inc. (CRI) stock, including its current price, historical performance, key financial statistics, and analyst insights. It details the company's business segments, product offerings, and market presence within the apparel retail sector, alongside comparative data with similar …

Criteo S.A. Stock 12‑Month Price Target Cut to $21.96, Implies 29% Upside

Analysts have revised the 12-month average price target for Criteo S.A. (CRTO) stock down slightly from $22.29 to $21.96, with forecasts ranging from $16 to $30 per share. This new target suggests a potential upside of approximately 29% based on the recent closing price. …

Cricut Inc (CRCT) Earnings Forecast: Future EPS & Revenue Growth Estimates

Cricut Inc (CRCT) currently has an earnings forecast score of 4.00, placing it 10th in the Integrated Hardware & Software industry, with an average price target of $3.75 from three analysts who generally recommend a "Sell" trend. The company's expected revenue for the next …

EW SCRIPPS ($SSP) Releases Q2 2026 Earnings

E.W. Scripps (NASDAQ:SSP) Misses Q2 CY2026 Sales Expectations

Criteo S.A. (NASDAQ: CRTO) officer plans sale of RSU and PSU shares

A recent Form 144 filing indicates that an officer of Criteo S.A. (NASDAQ: CRTO) plans to sell 15,906 ordinary shares related to restricted stock units and performance stock units vesting in February 2025. The anticipated sale date is August 6, 2026, with Citigroup Global …

Criteo S.A. (CRTO) holder files to sell 15,559 shares via Citigroup

A holder of Criteo S.A. (CRTO) ordinary shares has filed a Form 144 to sell up to 15,559 shares through Citigroup Global Markets Inc. on NASDAQ, valued at approximately $268,006.89. The planned sale is linked to equity compensation, including restricted stock units and performance …

Acrivon Therapeutics, Inc. (ACRV) CFO sells 1,142 shares to cover taxes

Acrivon Therapeutics, Inc.'s Chief Financial Officer, Adam D. Levy, sold 1,142 shares of common stock at $1.57 per share on August 4, 2026. This sale was automatically conducted to satisfy mandatory tax withholding requirements upon the vesting of restricted stock units. Following this transaction, …

PIMCO discloses 1.89M-share Carter's Inc (CRI) position in Schedule 13G

PIMCO has reported a 5.1% beneficial ownership stake in Carter's Inc. (CRI), totaling 1,890,588 shares of common stock. This disclosure was made in a Schedule 13G filing, indicating PIMCO, as an investment adviser, holds sole voting and dispositive power over these shares for its …

Crinetics Pharmaceuticals (CRNX) Stock Looks Rich On Book Value But Reasonable On Deal Value

Crinetics Pharmaceuticals (CRNX) has experienced a significant stock price increase of 403.6% over three years, making its current valuation appear high on market multiples. While the agreed acquisition by Vertex Pharmaceuticals for US$10.0 billion helps justify the current price, the stock's Price-to-Book ratio of …